li

Design Therapeutics launches with $45 million for neurological diseases




li

Thermo Fisher to invest $475 million in biopharmaceutical services




li

What can initial remdesivir data tell us about tackling COVID-19?

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts




li

US government allows grant funding flexibility during coronavirus outbreak




li

Jen Heemstra on building your resilience

C&EN advice columnist offers 4 tips on adapting to times of uncertainty




li

COVID-19 to delay clinical trials

Drugmakers want to keep trials going but acknowledge that medical resources are strained




li

Journal publishers promote flexibility during COVID-19 pandemic

Editors in Europe and the US plan to work with authors whose lives and labs have been disrupted by the novel coronavirus




li

Covestro borrows $240 million for sustainability R&D




li

Life sciences consortium connects with Gates Foundation to tackle COVID-19




li

Lilly and Sitryx sign immunotherapy pact




li

Novel coronavirus thought to have jumped to humans via pangolins

Trafficked scaly anteaters found to carry coronaviruses related to SARS-CoV-2




li

Combining heat with light boosts methanol synthesis from CO<sub>2</sub>

Study unravels reaction mechanism occurring on common catalyst




li

Meet Sheng Ding, who is tackling COVID-19 as director of China's Global Health Drug Discovery Institute

The chemist wants the Gates Foundation–backed institute to share its expertise during the coronavirus pandemic and advocate for public health




li

Clinical trial for ruxolitinib planned in fight against COVID-19

Treatment for rare blood cancers could temper cytokine storm in people with severe forms of the disease




li

India partially lifts drug export ban on hydroxychloroquine and acetaminophen

Country will now allow exports if domestic needs are met to treat COVID-19




li

Clinical trial for ruxolitinib planned in fight against COVID-19

Treatment for rare blood cancers could temper cytokine storm in people with severe forms of the disease




li

Industry requests safety review of cyclic siloxane

US EPA considers evaluating risks of D4 under the Toxic Substances Control Act




li

Rgenta Therapeutics launches with $20 million to develop small molecules that target RNA




li

AGC will expand Spanish API facility




li

Gilead strikes deal with microbiome specialist Second Genome




li

Air Liquide negotiates sale of hygiene unit




li

Plasmonic color offers durability, ultra-high resolution, and low cost

The phenomenon behind the earliest photographs is making a comeback, inspiring new research in color printing and displays




li

Pentachlorophenol is on its way out as a utility pole preservative. Here's what might take its place

Phaseout is pushing a slow-to-change industry to look at alternatives




li

US EPA won't strengthen particulate matter limit

Chemical industry backs plan to keep current standard




li

Structure of SARS-CoV-2 RNA-dependent RNA polymerase published

Researchers use cryo-EM to image the viral protein that remdesivir targets




li

COVID-19 vaccines are moving toward clinical trials

Tests of 10 or more novel vaccines could be underway by mid-May




li

How to add a carbonyl to a molecule using carbon monoxide and light

Palladium-catalyzed reaction makes acid chlorides, amides, esters, and ketones from both alkyl and aryl halides




li

Lilly will test baricitinib against COVID-19




li

MOMA Therapeutics launches with $86 million series A to drug molecular machines




li

ACS Publications expands remote access




li

Spring ACS Board and Council Policy Committee actions




li

i2O launches for ionic liquid–based drug delivery




li

Agilyx licenses polystyrene recycling technology in Japan




li

North Carolina rejects Chemours's PFAS cleanup plan




li

Industry requests safety review of cyclic siloxane

US EPA considers evaluating risks of D4 under the Toxic Substances Control Act




li

Scaling up remdesivir amid the coronavirus crisis

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment




li

COVID-19 claims the life of beloved chemistry professor

Dennis Peters of Indiana University dies from complications of COVID-19




li

Scaling up remdesivir amid the coronavirus crisis

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment




li

Seedling aroma attracts stink bug invaders

The identification of brassicadiene could help protect cauliflower and broccoli crops from the ravenous insects




li

Courts lean against US EPA science advisers policy

Trial court vacates directive, appeals courts appear skeptical of legality




li

Bill Suits dies of COVID-19 complications

ACS volunteer was passionate about mentoring students and helping chemists find jobs




li

Clinical trials planned to put hydroxychloroquine to the test for COVID-19

The antimalaria drug will be tested for treating or preventing the disease in thousands of people worldwide




li

Michelin partners with Enviro to recycle tires with pyrolysis




li

Nitrome raises $38 million to drug Parkinson's enzyme




li

US funding agencies move grant review panels online

NSF, NIH were prepared for the quick transition to virtual meetings




li

Sweet-smelling study aids, and why stinky plastic is a trap for turtles




li

Silicon-carbonyl complex is stable at room temperature

Electron-rich compound reacts like a transition metal




li

Does the FDA's authorization for chloroquine impede clinical trials for COVID-19 drugs?

Despite the hype, support for the use of chloroquine and its relative hydroxychloroquine outside a clinical trial remains mixed




li

As they scramble to shore up supplies, small firms brace for a recession

Early signs of a downturn in demand herald a season of unprecedented uncertainty




li

Gilead's remdesivir gets emergency use authorization based on preliminary data in COVID-19

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster